Table 1.

Registered clinical trials on clinicaltrials.gov focused on CD47-SIRP axis.

Sponsor (Lead Drug)	Clinical Trials.gov Identifier	Intervention	Cancer type	Phase
Gilead Magrolimab	NCT02953509	+ Rituximab	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	I/II
	NCT02953782	+ Cetuximab	Solid Tumors and advanced colorectal cancer;	I/II
	NCT03248479	Monotherapy or + Azacitidine	Hematological Malignancies	I
	NCT03558139	+ Avelumab	Ovarian Cancer	I
Celgene CC-90002	NCT02641002	Monotherapy	Acute myeloid leukemia; myelodysplastic syndromes	I
	NCT02367196	Monotherapy or + Rituximab	Hematologic Neoplasms
Surface Oncology SRF231	NCT03512340	Monotherapy	Advanced Solid and Hematologic Cancers	I
ALX Oncology ALX148	NCT03013218	Monotherapy or + Rituximab /Pembrolizumab /Trastuzumab	Advanced Solid Tumors and Lymphoma	I
Trillium TTI-621	NCT02663518	Monotherapy or +Rituximab /Nivolumab	Hematological Malignancies and Selected Solid Tumors	Ia/Ib
	NCT02890368	Monotherapy or + PD1/PD-L1 Inhibitor /pegylated interferon-α2a /T-Vec/radiation	Relapsed and Refractory Solid Tumors and Mycosis Fungoides	I
Trillium TTI-622	NCT03530683	+Rituximab	Relapsed or refractory lymphoma or myeloma	I
Arch Oncology AO-176	NCT03834948	Monotherapy	Multiple solid tumor malignancies	I
Innovent Biologics IBI188	NCT03763149	Monotherapy	Advanced malignant tumors and lymphomas	I
	NCT03717103	Monotherapy or + Rituximab	Advanced Malignancies	I